Duodenal mucosal ablation by irreversible electroporation: modulating the gut-liver axis in MASLD
In a rat model of high-fat diet-induced hepatic steatosis, duodenal mucosal ablation by irreversible electroporation reduced hepatic lipid accumulation and improved serum lipid profiles with favorable effects on intestinal barrier integrity — evidence is exclusively preclinical.
| Population | Male Sprague-Dawley rats with hepatic steatosis induced by an 8-week high-fat diet |
|---|---|
| Intervention | Duodenal mucosal ablation (DMA) by irreversible electroporation (IRE) over a 5 cm duodenal segment via custom catheter at 250 V/cm |
| Comparator | Sham procedure |
| Outcome | Hepatic steatosis (histology); Serum lipid profile; Duodenal villous length; Duodenal villous thickness; Intestinal barrier integrity (absence of complications) |
Summary of findings
| Outcome | Effect | 95% CI | Certainty | Clinical relevance | Notes |
|---|---|---|---|---|---|
| Hepatic steatosis (histology) | Qualitative reduction reported; in the standardized effect size or 95% CI available | — | Very low | — | 1 studies |
| Serum lipid profile | Qualitative improvement reported; in the standardized effect size or 95% CI available | — | Very low | — | 1 studies |
| Duodenal villous length | MD -284 μm (561±104 vs 845±74 μm), p<0.05; 95% CI not reported | — | Very low | — | 1 studies |
| Duodenal villous thickness | MD -67 μm (133±32 vs 200±110 μm), p<0.05; 95% CI not reported | — | Very low | — | 1 studies |
| Intestinal barrier integrity (absence of complications) | No perforation, hemorrhage, or stenosis at 2w; in the quantitative effect size available | — | Very low | — | 1 studies |
Context
MASLD is the most prevalent chronic liver disease worldwide and lacks effective minimally invasive interventions. The duodenum functions as a central metabolic and endocrine sensor in the gut-liver axis, and its dysfunction contributes to dysbiosis, increased intestinal permeability, and hepatic inflammation. Duodenum-targeted interventions represent an emerging research avenue without human clinical validation.
What the study showed
The DMA group showed narrower villi (thickness: 133 ± 32 μm vs 200 ± 110 μm; p < 0.05) and shorter villi (length: 561 ± 104 μm vs 845 ± 74 μm; p < 0.05) compared to sham. Hepatic lipid accumulation was reduced and serum lipid profiles improved in the intervention group. Intestinal barrier integrity was preserved, with no perforation, hemorrhage, or stenosis at 2-week follow-up. Full confidence intervals and standardized effect sizes were not reported in the available letter text.
How it was done
Scientific letter analyzing a primary preclinical study (Yu et al, World J Gastroenterol) using male Sprague-Dawley rats fed a high-fat diet for 8 weeks, randomized to DMA-IRE or sham. Follow-up was 2 weeks post-procedure. The full text of the primary study was not provided; data extracted from the analytical letter.
Effect magnitude
Villous thickness decreased from 200 to 133 μm (33.5% reduction) and villous length from 845 to 561 μm (33.6% reduction); p < 0.05. 95% CI and standardized effect sizes were not reported.
Risk of bias
Animal model (rat) with only 2-week post-ablation follow-up, without long-term data. Absence of 95% CI and standardized effect size measures. No risk-of-bias tool applied (SYRCLE would be appropriate for preclinical studies). Generalization to humans is speculative; this is a secondary analytical letter with partial access to the original study.
What this study does NOT prove
This study does not prove efficacy or safety in humans, nor causality between duodenal remodeling and MASLD regression in any species beyond rats. It does not demonstrate impact on hepatic fibrosis, mortality, or clinically relevant outcomes.
In clinical practice
No established clinical indication exists for DMA-IRE in human MASLD. Clinicians should not modify practice based on these preclinical data. The study supports hypotheses for phase I/II clinical trials, not therapeutic protocols.
Limitations
Animal model (rat) with only 2-week post-ablation follow-up, without long-term data. Absence of 95% CI and standardized effect size measures. No risk-of-bias tool applied (SYRCLE would be appropriate for preclinical studies). Generalization to humans is speculative; this is a secondary analytical letter with partial access to the original study.
What is still missing
Phase I/II human trials in MASLD patients to evaluate safety, feasibility, and efficacy of DMA-IRE. Validated histological liver endpoints (NAS score, fibrosis staging) and follow-up ≥ 12 months are required.
Technical appendix
Version history
- 1.0 · 2026-06-21 — Auto-generated under Evidence Standard v1.0